,docId,isValid,passage,passage_id,e1,e2
0,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC102,TFIIIC63
1,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC102,TFIIIC
2,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0,TFIIIC63,TFIIIC
3,HPRD50.d1,True,"Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2",HPRD50.d1.s0,monocyte chemotactic protein-1,CCR2
4,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1,MCP-1,RANTES
5,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1,MCP-1,IL-8
6,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1,RANTES,IL-8
7,HPRD50.d1,True,It was previously shown that the N-terminus of CCR2 is critical for binding MCP-1,HPRD50.d1.s2,CCR2,MCP-1
8,HPRD50.d1,True,"To identify the regions of MCP-1 that contact its receptor, CCR2, we substituted all surface-exposed residues with alanine",HPRD50.d1.s3,MCP-1,CCR2
9,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0,CG beta,CG beta alpha
10,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0,CG beta,FSH beta
11,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0,CG beta alpha,FSH beta
12,HPRD50.d2,False,The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/CG beta subunit since CG single chain interacts with the monomeric FSH beta subunit and exhibits FSH activity,HPRD50.d2.s1,CG beta,FSH beta
13,HPRD50.d2,False,"This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the LH beta or FSH beta subunits are different",HPRD50.d2.s2,LH beta,FSH beta
14,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3,CG beta,FSH beta
15,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3,CG beta,CG beta alpha
16,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3,FSH beta,CG beta alpha
17,HPRD50.d3,True,"Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines",HPRD50.d3.s0,Interleukin-6,phosphatidylinositol-3 kinase
18,HPRD50.d3,False,RESULTS: Tyrosine phosphorylation of p85 is upregulated by IL-6 in both LNCaP and PC-3,HPRD50.d3.s1,IL-6,PC-3
19,HPRD50.d3,True,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2,IL-6,gp130
20,HPRD50.d3,False,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2,IL-6,IL-6 receptor
21,HPRD50.d3,False,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2,gp130,IL-6 receptor
22,HPRD50.d4,False,"In solution, FGFR4ed formed complexes with acidic FGF (FGF-1) and basic FGF (FGF-2), both in the presence and absence of heparin",HPRD50.d4.s0,acidic FGF (FGF-1),basic FGF (FGF-2)
23,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGFR4,FGF-8
24,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGFR4,FGF-1
25,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGFR4,FGF-2
26,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGF-8,FGF-1
27,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGF-8,FGF-2
28,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1,FGF-1,FGF-2
29,HPRD50.d5,True,Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1,HPRD50.d5.s0,Cytohesin-1,LFA-1
30,HPRD50.d5,True,"Here we provide evidence of how cytohesin-1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for ARF GTPases, regulates cell adhesion",HPRD50.d5.s1,cytohesin-1,ARF
31,HPRD50.d5,True,"Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of LFA-1 depends on its interaction with cytohesin-1, unless the integrin is activated by exogenous divalent cations",HPRD50.d5.s2,LFA-1,cytohesin-1
32,HPRD50.d5,True,"Secondly, cytohesin-1 induces expression of an extracellular activation epitope of LFA-1, and the exchange factor function is not essential for this activity",HPRD50.d5.s3,cytohesin-1,LFA-1
33,HPRD50.d5,True,"In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a cytohesin-1 mutant, which fails to catalyze ARF GDP-GTP exchange in vitro",HPRD50.d5.s4,cytohesin-1,ARF
34,HPRD50.d5,True,"Thus, cytohesin-1 is involved in the activation of LFA-1, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity",HPRD50.d5.s5,cytohesin-1,LFA-1
35,HPRD50.d7,True,Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2,HPRD50.d7.s0,peroxisome proliferator-activated receptor gamma,NRF2
36,HPRD50.d7,False,"Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 (NF-E2)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene",HPRD50.d7.s1,NF-E2,AP-1
37,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,NF-E2,AP-1
38,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,NF-E2,NRF2
39,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,NF-E2,NF-E2-related factor 2
40,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,AP-1,NRF2
41,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,AP-1,NF-E2-related factor 2
42,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2,NRF2,NF-E2-related factor 2
43,HPRD50.d7,False,"Finally, a direct interaction between PPARgamma and NRF2 was confirmed by glutathione S-transferase pull-down assay",HPRD50.d7.s3,NRF2,glutathione S-transferase
44,HPRD50.d8,False,"By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to Hsp90 and amino acid residues 327-340 of Hsp90beta were involved in the binding to Akt",HPRD50.d8.s0,Hsp90,Hsp90beta
45,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0,KIAA1427,Syt
46,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0,KIAA1427,Syt XIII
47,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0,Syt,Syt XIII
48,HPRD50.d9,False,"Subcellular fractionation and antibody-uptake experiments indicate that Syt XIII is indeed a type-I membrane protein, but, unlike other Syt isoforms, lacks an N-terminal extracellular domain",HPRD50.d9.s1,Syt XIII,Syt
49,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0,ADAM 12,p85alpha
50,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0,ADAM 12,phosphatidylinositol 3-kinase
51,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0,p85alpha,phosphatidylinositol 3-kinase
52,HPRD50.d11,True,"This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85alpha, activates PI 3-kinase by mediating its recruitment to the membrane",HPRD50.d11.s1,ADAM 12,p85alpha
53,HPRD50.d12,True,AP180 binds to the C-terminal SH2 domain of phospholipase C-gamma1 and inhibits its enzymatic activity,HPRD50.d12.s0,AP180,phospholipase C-gamma1
54,HPRD50.d12,True,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,PLCgamma1,AP180
55,HPRD50.d12,True,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,AP180,PLCgamma1
56,HPRD50.d12,False,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1,PLCgamma1,PLCgamma1
57,HPRD50.d13,True,Here we demonstrate colocalization and direct interaction between CLIP-170 and LIS1,HPRD50.d13.s0,CLIP-170,LIS1
58,HPRD50.d13,True,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,phospho-LIS1
59,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,CLIP-170
60,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,LIS1
61,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,phospho-LIS1,CLIP-170
62,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,phospho-LIS1,LIS1
63,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1,CLIP-170,LIS1
64,HPRD50.d13,True,"This work suggests that LIS1 is a regulated adapter between CLIP-170 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics",HPRD50.d13.s2,LIS1,CLIP-170
65,HPRD50.d14,False,Megalin and cubilin: multifunctional endocytic receptors,HPRD50.d14.s0,Megalin,cubilin
66,HPRD50.d14,True,Megalin and cubilin are two structurally different endocytic receptors that interact to serve such functions,HPRD50.d14.s1,Megalin,cubilin
67,HPRD50.d16,True,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45b,cdc2
68,HPRD50.d16,True,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45g,cdc2
69,HPRD50.d16,False,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0,GADD45b,GADD45g
70,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45
71,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45b
72,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,MyD118
73,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,Gadd45g
74,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45a,CR6
75,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,Gadd45b
76,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,MyD118
77,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,Gadd45g
78,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45,CR6
79,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,MyD118
80,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,Gadd45g
81,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45b,CR6
82,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,MyD118,Gadd45g
83,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,MyD118,CR6
84,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1,Gadd45g,CR6
85,HPRD50.d16,True,Recent evidence has implicated Gadd45a in inhibition of cdc2/cyclinB1 kinase and in G2/M cell cycle arrest,HPRD50.d16.s2,Gadd45a,cdc2
86,HPRD50.d16,True,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45b,cdc2
87,HPRD50.d16,True,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45g,cdc2
88,HPRD50.d16,False,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3,Gadd45b,Gadd45g
89,HPRD50.d16,True,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45b,Cdk1
90,HPRD50.d16,True,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45g,Cdk1
91,HPRD50.d16,False,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4,Gadd45b,Gadd45g
92,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Cdk1
93,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Cdk1
94,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,Cdk1
95,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,Cdk1
96,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,GADD45a,Cdk1
97,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,GADD45a,Cdk1
98,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,Gadd45g
99,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45b,GADD45a
100,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Gadd45g,GADD45a
101,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5,Cdk1,Cdk1
102,HPRD50.d16,True,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45b
103,HPRD50.d16,True,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45a
104,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Cdk1,Gadd45g
105,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Gadd45b,Gadd45a
106,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Gadd45b,Gadd45g
107,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6,Gadd45a,Gadd45g
108,HPRD50.d18,True,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0,receptor protein tyrosine phosphatase,p120(ctn)
109,HPRD50.d18,True,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0,DEP1,p120(ctn)
110,HPRD50.d18,False,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0,receptor protein tyrosine phosphatase,DEP1
111,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,receptor-like protein tyrosine phosphatase,DEP1
112,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,receptor-like protein tyrosine phosphatase,CD148
113,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1,DEP1,CD148
114,HPRD50.d18,True,DEP1 also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin,HPRD50.d18.s2,DEP1,beta-catenin
115,HPRD50.d18,False,"The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression",HPRD50.d18.s3,p120(ctn),E-cadherin
116,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4,PTP-PEST,CD45
117,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4,PTP-PEST,DEP1
118,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4,CD45,DEP1
119,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,MEF2A
120,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,cAMP-response-element-binding-protein,MEF2A
121,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,CREB,MEF2A
122,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,cAMP-response-element-binding-protein
123,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,p300,CREB
124,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0,cAMP-response-element-binding-protein,CREB
125,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,p300,cAMP-response-element-binding-protein
126,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,p300,CREB
127,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1,cAMP-response-element-binding-protein,CREB
128,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,p300,MEF2A
129,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,MEF2A,p300
130,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,p300,MEF2A
131,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,p300,p300
132,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,MEF2A,MEF2A
133,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2,MEF2A,p300
134,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp3,Imp4
135,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp3,snoRNA
136,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0,Imp4,snoRNA
137,HPRD50.d20,False,We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4,HPRD50.d20.s1,Imp3,Imp4
138,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp4,Imp3
139,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp4,Imp3
140,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2,Imp3,Imp3
141,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp3,snoRNA
142,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp4,snoRNA
143,HPRD50.d20,False,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3,Imp3,Imp4
144,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0,CB1,orexin 1 receptor
145,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0,CB1,OX1R
146,HPRD50.d21,False,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0,orexin 1 receptor,OX1R
147,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1,OX1R,CB1
148,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1,OX1R,OX1R
149,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1,CB1,OX1R
150,HPRD50.d21,False,"In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers",HPRD50.d21.s2,CB1,OX1R
151,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GC-GAP,Gab1
152,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GC-GAP,Gab2
153,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GTPase-activating protein,Gab1
154,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GTPase-activating protein,Gab2
155,HPRD50.d22,False,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,GC-GAP,GTPase-activating protein
156,HPRD50.d22,False,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0,Gab1,Gab2
157,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Grb2
158,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Shp-2
159,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,phosphatidylinositol 3-kinase
160,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab2,Grb2
161,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab2,Shp-2
162,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab2,phosphatidylinositol 3-kinase
163,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Gab1,Gab2
164,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Grb2,Shp-2
165,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Grb2,phosphatidylinositol 3-kinase
166,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1,Shp-2,phosphatidylinositol 3-kinase
167,HPRD50.d22,True,"In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro",HPRD50.d22.s2,GC-GAP,Nck
168,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab1,GC-GAP
169,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab1,Cdc42
170,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab2,GC-GAP
171,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab2,Cdc42
172,HPRD50.d22,False,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,Gab1,Gab2
173,HPRD50.d22,False,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3,GC-GAP,Cdc42
174,HPRD50.d22,False,This work led to identification of a novel GTPase-activating protein (GAP) for Rho family GTPases,HPRD50.d22.s4,GTPase-activating protein,GAP
175,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5,CdGAP,Rac1
176,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5,CdGAP,Cdc42
177,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5,Rac1,Cdc42
178,HPRD50.d22,True,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6,GC-GAP,GAB
179,HPRD50.d22,True,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6,GC-GAP,Cdc42
180,HPRD50.d22,False,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6,GAB,Cdc42
181,HPRD50.d22,True,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7,GC-GAP,Rac1
182,HPRD50.d22,True,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7,GC-GAP,Cdc42
183,HPRD50.d22,False,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7,Rac1,Cdc42
184,HPRD50.d23,True,A role for Plk1 phosphorylation of NudC in cytokinesis,HPRD50.d23.s0,Plk1,NudC
185,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
186,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
187,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
188,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,Plk1
189,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
190,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
191,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,Plk1
192,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
193,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
194,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
195,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
196,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,NudC
197,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,Plk1,Plk1
198,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,NudC
199,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1,NudC,Plk1
200,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
201,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
202,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
203,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,NudC
204,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
205,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2,NudC,Plk1
206,HPRD50.d23,True,These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis,HPRD50.d23.s3,Plk1,NudC
207,HPRD50.d24,True,Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene,HPRD50.d24.s0,Egr1,low density lipoprotein receptor
208,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,oncostatin M
209,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDLR,oncostatin M
210,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,oncostatin M,LDLR
211,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,LDLR
212,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDL receptor,LDLR
213,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1,LDLR,LDLR
214,HPRD50.d25,True,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0,TR2,androgen receptor
215,HPRD50.d25,False,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0,TR2,PC-3
216,HPRD50.d25,False,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0,androgen receptor,PC-3
217,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,androgen receptor,TR2
218,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,androgen receptor,TR2
219,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1,TR2,TR2
220,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,TR2,glutathione-S-transferase
221,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,TR2,GST
222,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2,glutathione-S-transferase,GST
223,HPRD50.d26,True,The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1 alpha for proteasomal degradation during normoxia,HPRD50.d26.s0,pVHL,Hif1 alpha
224,HPRD50.d26,True,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,pVHL,Tat-binding protein-1
225,HPRD50.d26,True,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,pVHL,TBP-1
226,HPRD50.d26,False,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1,Tat-binding protein-1,TBP-1
227,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,TBP-1,pVHL
228,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,TBP-1,pVHL
229,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,TBP-1,Hif1 alpha
230,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,pVHL,pVHL
231,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,pVHL,Hif1 alpha
232,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2,pVHL,Hif1 alpha
233,HPRD50.d26,True,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3,TBP-1,Hif1 alpha
234,HPRD50.d26,True,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3,Hif1 alpha,TBP-1
235,HPRD50.d26,False,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3,TBP-1,TBP-1
236,HPRD50.d26,True,Blockade of TBP-1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Hif1 alpha,HPRD50.d26.s4,TBP-1,Hif1 alpha
237,HPRD50.d26,True,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5,VHL,TBP-1
238,HPRD50.d26,True,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5,pVHL,TBP-1
239,HPRD50.d26,False,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5,VHL,pVHL
240,HPRD50.d26,True,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,pVHL,Hif1 alpha
241,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,pVHL,TBP-1
242,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,pVHL,Hif1 alpha
243,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,Hif1 alpha,TBP-1
244,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,Hif1 alpha,Hif1 alpha
245,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6,TBP-1,Hif1 alpha
246,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,pVHL,Hif1 alpha
247,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,pVHL,TBP-1
248,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,pVHL
249,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,pVHL,Hif1 alpha
250,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,pVHL,pVHL
251,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,TBP-1
252,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,Hif1 alpha
253,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,Hif1 alpha,pVHL
254,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,TBP-1,Hif1 alpha
255,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7,TBP-1,pVHL
256,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,SRp75
257,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,SRm300
258,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,DRS,SRp75
259,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,DRS,SRm300
260,HPRD50.d27,False,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,Pinin,DRS
261,HPRD50.d27,False,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0,SRp75,SRm300
262,HPRD50.d27,False,"Three SR-rich proteins were identified that interact with the C-terminus of Pnn: SRp75 and SRm300, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130",HPRD50.d27.s1,SRp75,SRm300
263,HPRD50.d29,True,Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription,HPRD50.d29.s0,Dnmt3a,SUMO-1
264,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,Ubc9
265,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,PIAS1
266,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,PIASxalpha
267,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Ubc9,SUMO-1
268,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,PIAS1,SUMO-1
269,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,PIASxalpha,SUMO-1
270,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Dnmt3a,SUMO-1
271,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Ubc9,PIAS1
272,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,Ubc9,PIASxalpha
273,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1,PIAS1,PIASxalpha
274,HPRD50.d29,True,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,Dnmt3a,SUMO-1
275,HPRD50.d29,False,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,Dnmt3a,Dnmt3a
276,HPRD50.d29,False,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2,SUMO-1,Dnmt3a
277,HPRD50.d29,True,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3,Dnmt3a,HDAC1
278,HPRD50.d29,False,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3,Dnmt3a,Dnmt3b
279,HPRD50.d29,False,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3,HDAC1,Dnmt3b
280,HPRD50.d30,True,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0,Tyk-2,IFN
281,HPRD50.d30,True,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0,Tyk-2,IFN alpha
282,HPRD50.d30,False,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0,IFN,IFN alpha
283,HPRD50.d31,True,Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation,HPRD50.d31.s0,Raf1,Cdc25
284,HPRD50.d31,True,We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes,HPRD50.d31.s1,Cdc25,raf1
285,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,biglycan
286,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,decorin
287,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,perlecan,versican
288,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,biglycan,decorin
289,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,biglycan,versican
290,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0,decorin,versican
291,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,beta-amyloid
292,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,amyloid
293,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,heparan sulfate proteoglycan,beta-amyloid
294,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,heparan sulfate proteoglycan,amyloid
295,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,perlecan,heparan sulfate proteoglycan
296,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1,beta-amyloid,amyloid
297,HPRD50.d32,False,"Overall, the results indicate that specific vascular cell-derived PGs differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of perlecan",HPRD50.d32.s2,PGs,perlecan
298,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,SMC,PGs
299,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,SMC,amyloid
300,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,SMC,perlecan
301,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,PGs,amyloid
302,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,PGs,perlecan
303,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3,amyloid,perlecan
304,HPRD50.d32,False,"Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase",HPRD50.d32.s4,perlecan,ABC
305,HPRD50.d32,False,"[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin",HPRD50.d32.s5,PGs,serum albumin
306,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,perlecan
307,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,decorin
308,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,biglycan
309,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,PGs
310,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,perlecan
311,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,decorin
312,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,biglycan
313,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,versican
314,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,SMC,PG-M
315,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,versican
316,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,PGs,PG-M
317,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,decorin
318,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,biglycan
319,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,versican
320,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,perlecan,PG-M
321,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,biglycan
322,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,versican
323,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,decorin,PG-M
324,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,biglycan,versican
325,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,biglycan,PG-M
326,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6,versican,PG-M
327,HPRD50.d33,True,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD53,CD69
328,HPRD50.d33,True,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD53,c-myc
329,HPRD50.d33,False,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0,CD69,c-myc
330,HPRD50.d33,True,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1,IL-2,CD53
331,HPRD50.d33,True,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1,IL-4,CD53
332,HPRD50.d33,False,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1,IL-2,IL-4
333,HPRD50.d34,False,The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases,HPRD50.d34.s0,apoB,cytidine deaminase
334,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1,apoB,homodimer
335,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1,apoB,apoB
336,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1,homodimer,apoB
337,HPRD50.d35,False,"Assignment of Etfdh, Etfb, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human",HPRD50.d35.s0,Etfdh,Etfb
338,HPRD50.d35,False,"We used cDNA probes for the Etfdh, Etfb, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13",HPRD50.d35.s1,Etfdh,Etfb
339,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,cystatin alpha
340,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,desmoplakin
341,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,elafin
342,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,loricrin
343,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,involucrin,desmoplakin
344,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,desmoplakin
345,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,elafin
346,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,loricrin
347,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,cystatin alpha,desmoplakin
348,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,desmoplakin,elafin
349,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,desmoplakin,loricrin
350,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,desmoplakin,desmoplakin
351,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,elafin,loricrin
352,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,elafin,desmoplakin
353,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0,loricrin,desmoplakin
354,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1,involucrin,desmoplakin
355,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1,involucrin,involucrin
356,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1,desmoplakin,involucrin
357,HPRD50.d39,True,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0,SRcyp,CTD
358,HPRD50.d39,True,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0,CASP10,CTD
359,HPRD50.d39,False,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0,SRcyp,CASP10
360,HPRD50.d39,False,SRcyp is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing splicing factor SC35,HPRD50.d39.s1,SRcyp,splicing factor SC35
361,HPRD50.d40,True,Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-1.B promoter activity,HPRD50.d40.s0,E2-2,FGF-1.B
362,HPRD50.d40,True,These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1,HPRD50.d40.s1,E2-2,FGF-1
